## **LISTING OF CLAIMS:**

1-22. (cancelled)

23. (withdrawn) A purified HIV-1 virus,

wherein said virus encodes a Gag protein comprising an amino acid sequence that comprises at least 1 amino acid residue of the amino acid sequence of HIV-1ELI that is not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.

- 24. (withdrawn) The HIV-1 virus of claim 23, wherein said amino acid sequence comprises 1 amino acid residue of the amino acid sequence of HIV-1ELI that is not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.
- 25. (withdrawn) The HIV-1 virus of claim 23, wherein said amino acid sequence comprises more than 1 amino acid residue of the amino acid sequence of HIV-1ELI that is not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.
- 26. (withdrawn) The HIV-1 virus of claim 25, wherein said amino acid sequence comprises 3 amino acid residues of the amino acid sequence of HIV-1ELI that are not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.
- 27. (withdrawn) The HIV-1 virus of claim 25, wherein said amino acid sequence comprises 5 amino acid residues of the amino acid sequence of HIV-1ELI that are not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

28. (withdrawn) The HIV-1 virus of claim 25, wherein said amino acid sequence comprises 7 amino acid residues of the amino acid sequence of HIV-1ELI that are not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.

29. (withdrawn) A purified HIV-1 virus,

wherein said virus encodes a Pol protein comprising an amino acid sequence that comprises at least 1 amino acid residue of the amino acid sequence of HIV-1ELI that is not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.

- 30. (withdrawn) The HIV-1 virus of claim 29, wherein said amino acid sequence comprises 1 amino acid residue of the amino acid sequence of HIV-1ELI that is not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.
- 31. (withdrawn) The HIV-1 virus of claim 29, wherein said amino acid sequence comprises more than 1 amino acid residue of the amino acid sequence of HIV-1ELI that is not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.
- 32. (withdrawn) The HIV-1 virus of claim 31, wherein said amino acid sequence comprises 3 amino acid residues of the amino acid sequence of HIV-1ELI that are not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.
- 33. (withdrawn) The HIV-1 virus of claim 31, wherein said amino acid sequence comprises 5 amino acid residues of the amino acid sequence of HIV-1ELI

FINNEGAN HENDERSON FARABOW GARRETT & DUNNERLLP

that are not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.

- 34. (withdrawn) The HIV-1 virus of claim 31, wherein said amino acid sequence comprises 7 amino acid residues of the amino acid sequence of HIV-1ELI that are not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.
  - 35. (currently amended) A purified HIV-1 virus,

wherein said virus encodes an Env protein comprising having an amino acid sequence comprising amino acids of HIV-1ELI Env protein, that comprises

wherein said amino acids of HIV-1ELI Env protein comprise at least 1 amino acid residue of the amino acid sequence of HIV-1ELI that is not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2, and

wherein said amino acid residue is selected from the group consisting of S<sup>63</sup>, E<sup>65</sup>, A<sup>68</sup>, I<sup>71</sup>, I<sup>87</sup>, A<sup>88</sup>, E<sup>90</sup>, A<sup>215</sup>, R<sup>244</sup>, D<sup>245</sup>, K<sup>247</sup>, I<sup>286</sup>, Q<sup>509</sup>, R<sup>519</sup>, E<sup>526</sup>, or Q<sup>697</sup>, as described in Figures 3E and 3F.

- 36. (previously presented) The HIV-1 virus of claim 35, wherein said amino acid sequence comprises 1 amino acid residue of the amino acid sequence of HIV-1ELI that is not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.
- 37. (previously added) The HIV-1 virus of claim 35, wherein said amino acid sequence comprises more than 1 amino acid residue of the amino acid sequence of HIV-1ELI that is not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

38. (previously presented) The HIV-1 virus of claim 37, wherein said amino acid sequence comprises 3 amino acid residues of the amino acid sequence of HIV-1ELI that are not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.

- 39. (previously presented) The HIV-1 virus of claim 37, wherein said amino acid sequence comprises 5 amino acid residues of the amino acid sequence of HIV-1ELI that are not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.
- 40. (previously presented) The HIV-1 virus of claim 37, wherein said amino acid sequence comprises 7 amino acid residues of the amino acid sequence of HIV-1ELI that are not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.
- 41. (withdrawn) A purified HIV-1 polypeptide fragment, wherein said polypeptide fragment binds to antibodies in LAS patient sera, and wherein said polypeptide fragment comprises an amino acid sequence that comprises at least 1 amino acid residue of the amino acid sequence of HIV-1ELI that is not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.
- 42. (withdrawn) The polypeptide fragment of claim 41, wherein said polypeptide fragment comprises 1 amino acid residue of the amino acid sequence of HIV-1ELI that is not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.
- 43. (withdrawn) The polypeptide fragment of claim 41, wherein said polypeptide fragment comprises more than 1 amino acid residue of the amino acid

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

sequence of HIV-1ELI that is not present in the amino acid sequence of HIV-1IIB, HIV-1BRU, or HIV-1ARV-2.

- 44. (withdrawn) The polypeptide fragment of claim 43, wherein said polypeptide fragment comprises 3 amino acid residues of the amino acid sequence of HIV-1ELI that are not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.
- 45. (withdrawn) The polypeptide fragment of claim 43, wherein said polypeptide fragment comprises 5 amino acid residues of the amino acid sequence of HIV-1ELI that are not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.
- 46. (withdrawn) The polypeptide fragment of claim 43, wherein said polypeptide fragment comprises 7 amino acid residues of the amino acid sequence of HIV-1ELI that are not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.
- 47. (withdrawn) The polypeptide fragment of any of claims 41-46, wherein said polypeptide fragment comprises 5-150 amino acid residues.
- 48. (withdrawn) The polypeptide fragment of claim 47, wherein said polypeptide fragment comprises 5-250 amino acid residues.
- 49. (withdrawn) The polypeptide fragment of claim 47, wherein said polypeptide fragment comprises one or more Asn-X-Thr or Asn-X-Ser groups.
- 50. (withdrawn) The polypeptide fragment of any of claims 41-46, wherein said polypeptide fragment is a fragment of HIV-1 Gag.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

51. (withdrawn) The polypeptide fragment of any of claims 41-46, wherein said polypeptide fragment is a fragment of HIV-1 Pol.

52. (withdrawn) The polypeptide fragment of any of claims 41-46, wherein said polypeptide fragment is a fragment of HIV-1 Env.

53. (withdrawn) A purified HIV-1 nucleic acid fragment,
wherein said nucleic acid fragment encodes a polypeptide fragment,
wherein said polypeptide fragment binds to antibodies in LAS patient sera, and
wherein said polypeptide fragment comprises an amino acid sequence that
comprises at least 1 amino acid residue of the amino acid sequence of HIV-1ELI that
is not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.

54. (withdrawn) The nucleic acid fragment of claim 53, wherein said encoded polypeptide fragment comprises 1 amino acid residue of the amino acid sequence of HIV-1ELI that is not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.

55. (withdrawn) The nucleic acid fragment of claim 53, wherein said encoded polypeptide fragment comprises more than 1 amino acid residue of the amino acid sequence of HIV-1ELI that is not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.

56. (withdrawn) The nucleic acid fragment of claim 55, wherein said encoded polypeptide fragment comprises 3 amino acid residues of the amino acid sequence of HIV-1ELI that are not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

D<sup>d</sup> Appli

57. (withdrawn) The nucleic acid fragment of claim 55, wherein said encoded polypeptide fragment comprises 5 amino acid residues of the amino acid sequence of HIV-1ELI that are not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.

- 58. (withdrawn) The nucleic acid fragment of claim 55, wherein said encoded polypeptide fragment comprises 7 amino acid residues of the amino acid sequence of HIV-1ELI that are not present in the amino acid sequence of HIV-1IIIB, HIV-1BRU, or HIV-1ARV-2.
- 59. (withdrawn) The nucleic acid fragment of any of claims 53-58, wherein said encoded polypeptide fragment comprises 5-150 amino acid residues.
- 60. (withdrawn) The nucleic acid fragment of claim 59, wherein said encoded polypeptide fragment comprises 5-250 amino acid residues.
- 61. (withdrawn) The nucleic acid fragment of claim 59, wherein said encoded polypeptide fragment comprises one or more Asn-X-Thr or Asn-X-Ser groups.
- 62. (withdrawn) The nucleic acid fragment of any of claims 53-58, wherein said polypeptide fragment is a fragment of HIV-1 Gag.
- 63. (withdrawn) The nucleic acid fragment of any of claims 53-58, wherein said polypeptide fragment is a fragment of HIV-1 Pol.
- 64. (withdrawn) The nucleic acid fragment of any of claims 53-58, wherein said polypeptide fragment is a fragment of HIV-1 Env.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP